World AIDS Day 2015
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version
International Guidelines on HIV/AIDS and Human Rights 2006 Consolidated Version Second International Consultation on HIV/AIDS and Human Rights Geneva, 23-25 September 1996 Third International Consultation on HIV/AIDS and Human Rights Geneva, 25-26 July 2002 Organized jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS OFFICE OF THE UNITED NATIONS HIGH COMMISSIONER FOR HUMAN RIGHTS Material contained in this publication may be freely quoted or reprinted, provided credit is given and a copy containing the reprinted material is sent to the Office of the United Nations High Commissioner for Human Rights, CH-1211 Geneva 10, and to UNAIDS, CH-1211 Geneva 27, Switzerland. The designations employed and the presentation of the material in this publication do not imply expression of any opinion whatsoever on the part of the Secretariat of the United Nations or UNAIDS concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Published jointly by the Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on HIV/AIDS. HR/PUB/06/9 UN PUBLICATION Sales No. E.06.XIV.4 ISBN 92-1-154168-9 © Joint United Nations Programme on HIV/AIDS (UNAIDS) 2006. All rights reserved. Publications produced by UNAIDS can be obtained from the UNAIDS Information Centre. Requests for permission to translate UNAIDS publications—whether for sale or for noncommercial distribution—should also be addressed to the Information Centre at the address below, or by fax, at +41 22 791 4187, or e-mail: [email protected]. -
HIV Infection, AIDS, and Cancer
cancer.org | 1.800.227.2345 HIV Infection, AIDS, and Cancer People with HIV infection or AIDS are at higher risk for some types of cancer than people who are not infected. Here we will discuss the risks of certain cancers in people with HIV infection or AIDS, what tests these people might need to look for cancers early, and how these cancers are generally treated. ● What Are HIV and AIDS? ● How Are HIV and AIDS Related to Cancer? ● What Can People with HIV or AIDS Do to Try to Lower Their Risk of Cancer or Find It Early? ● How Is Cancer Treated in People with HIV or AIDS? What Are HIV and AIDS? Acquired immune deficiency syndrome, better known as AIDS, is caused by infection with the human immunodeficiency virus (HIV). AIDS is the most advanced stage of HIV infection. Over time, the virus attacks and destroys the body’s immune system (the system that protects the body from disease). Without a fully working immune system, a person is at risk for getting other infections that usually don’t affect healthy people. These are called opportunistic infections. People with HIV also have a greater risk of getting certain types of cancer, such as Kaposi sarcoma1, lymphoma2, and cervical cancer3, as well as other health problems. Many of these problems can threaten life. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 More than 1 million people in the United States are now living with HIV infection, and nearly 500,000 are living with AIDS. Women account for about 1 out of 4 people infected with HIV in this country. -
Hiv/Aids and Its Impact Hiv/Aids
Section 1 HIV/AIDS and its impact Section 2 Legal and policy HIV/AIDS AND ITS IMPACT framework Section 3 Employers need a clear understanding of HIV/AIDS and the impact of the epidemic in order to plan a workplace programme. Developing workplace policies This Section helps you fi nd basic information about inf HIV and inf AIDS, and their implications for society as a whole as well as for Section 4 the world of work. Implementing workplace programmes To view the contents, click on the headings on the left or scroll through the pages. Section 5 Good practice and lessons learnt HIV/AIDS - the facts The Human Immunodefi ciency Virus (HIV) is a virus that weakens the body’s immune system, ultimately causing AIDS. The Acquired Immune Defi ciency Syndrome (AIDS) is a cluster of medical conditions linke to HIV infection. These conditions include diseases known as inf 2 opportunistic infections, as well as certain cancers. To date there is no cure, but the onset of AIDS can be slowed and symptoms relieved with the appropriate use of antiretroviral drugs (ARVs). A person with HIV is not necessarily sick, and can go on working for a number of years after infection. ARVs make it possible for people to continue living full and productive lives. You are in Section 1 The ILO Code of Practice on HIV/AIDS and the world of work (Appendix I) and the accompanying HIV/AIDS and its impact Education and Training Manual contain basic facts about the epidemic and its implications, conditions that contribute to inf HIV and AIDS – the facts vulnerability, and the gender dimension. -
HIV DRUG RESISTANCE EARLY WARNING INDICATORS World Health Organization Indicators to Monitor HIV Drug Resistance Prevention at Antiretroviral Treatment Sites
HIV DRUG RESISTANCE EARLY WARNING INDICATORS World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update ACKNOWLEDGEMENTS The preparation of this document would not have been possible without the participation and assistance of many experts. Their work helped us to define HIV Drug Resistance Early Warning Indicators and to put together this guidance document. The World Health Organization wishes to acknowledge comments and contributions of the following individuals on the original guidance document, published in 2008: John Aberle-Grasse (Centers for Disease Control and Prevention, USA) David Bangsberg University of California-San Francisco, USA), George Bello (Ministry of Health, Malawi), Andrea De Luca (Università Cattolica of Rome, Italy), Caroline Fonck (WHO Haiti), Guy-Michel Gershy-Damet (WHO Africa Regional Office/Inter- Country Support Team, Burkina Faso), Bethany Hedt (Centers for Disease Control and Prevention, Malawi), Michael Jordan (Tufts University School of Medicine, USA) , Sidibe Kassim (Centers for Disease Control and Prevention, USA), Velephi Okello (Ministry of Health and Social Welfare, Swaziland), Padmini Srikantiah (WHO South East Asia Regional Office), Zeenat Patel (WHO Western Pacific Regional Office), and Nellie Wadonda-Kabondo (Ministry of Health, Malawi). Dongbao Yu (WHO Western Pacific Regional Office) provided input on the 2010 update. The original work was coordinated by Diane Bennett, Silvia Bertagnolio, Giovanni Ravasi (WHO/HTM/HIV, Geneva, -
Individual Responsibility Concerning HIV
SIT Graduate Institute/SIT Study Abroad SIT Digital Collections Independent Study Project (ISP) Collection SIT Study Abroad Fall 2006 Individual Responsibility Concerning HIV Transmission Among MSM: A Comparative Study of the Effectiveness of NGO Intervention Policies and Their rP actical Applications Within the United Kingdom, Australia, and the Netherlands Martha Kienbaum SIT Study Abroad Follow this and additional works at: https://digitalcollections.sit.edu/isp_collection Part of the Mass Communication Commons, and the Public Health Education and Promotion Commons Recommended Citation Kienbaum, Martha, "Individual Responsibility Concerning HIV Transmission Among MSM: A Comparative Study of the Effectiveness of NGO Intervention Policies and Their rP actical Applications Within the United Kingdom, Australia, and the Netherlands" (2006). Independent Study Project (ISP) Collection. 290. https://digitalcollections.sit.edu/isp_collection/290 This Unpublished Paper is brought to you for free and open access by the SIT Study Abroad at SIT Digital Collections. It has been accepted for inclusion in Independent Study Project (ISP) Collection by an authorized administrator of SIT Digital Collections. For more information, please contact [email protected]. Individual Responsibility Concerning HIV Transmission Among MSM: A comparative study of the effectiveness of NGO intervention policies and their practical applications within the United Kingdom, Australia, and the Netherlands “We need to break the silence, banish the stigma and discrimination and ensure total inclusiveness within the struggle against AIDS.” Nelson Mandela Martha Kienbaum Fall 2006 School for International Training Amsterdam Project Advisor: Tobias Dörfler Academic Advisor: Ginni Fleck 1 Abstract This study investigates the complexities involved in utilizing the terms of individual responsibility for the construction of HIV prevention campaigns that target men who have sex with men. -
AMA-MSS Guide to Organizing a World AIDS Day Event
MSS Guide to Organizing a World AIDS Day Event What’s inside? Instructions for Organizing your Event Pages 2-6 • Objectives • Materials • Event overview - day of the event • Step-by-step instructions and timeline • Funding sources • Follow-up Flier Template to Promote your Event Page 7 HIV/AIDS Movies Page 8 Media Advisory Template Page 9 Media Advisory Example Page 10 Objectives 1. Educate individuals about the impact of HIV and AIDS in the global community as well as your own. 2. Provide exhibits, speakers, movie screenings, demonstrations, and/or screenings focused towards individuals in your community. 3. Organize with different organizations and healthcare providers in the community to generate goodwill 4. Generate positive publicity for those organizations and individuals who are devoting their time for the benefit of World AIDS Day. 5. Empower participants with a better understanding of the many means in which they can help with the global AIDS epidemic. Back to top Materials 1. Laptop Computers for Possible Demonstrations and Mini-Workshops 2. Projectors to Enhance Computer or Personal Presentations 3. Materials for Featured Event – Discussion Forum, Speaker, Movie Screening 4. Fliers 5. Camera 6. Handouts – Relevant Information regarding the global AIDS epidemic Back to top World AIDS Day Forum – Day of the Event (December 1st) 1. Opening Remarks • General introduction, including a moment of thanks, to all of the different organizations for volunteering their time and/or money. • Explain the objective of the event as stated above. • Describe the schedule for the participants. There may be many items or there may be very few but make sure that all participants know what is offered. -
HIV/AIDS: China's Titanic Peril
HIV/AIDS: China's Titanic Peril 2001 Update of the AIDS Situation and Needs Assessment Report by The UN Theme Group on HIV/AIDS in China HIV/AIDS: China's Titanic Peril 2001 Update of the AIDS Situation and Needs Assessment Report This report was prepared by the UN Theme Group on HIV/AIDS in China for the UN Country Team June 2002 2 HIV/AIDS: China’s Titanic Peril Glossary of Abbreviations AIDS Acquired Immune Deficiency Syndrome CBO Community Based Organisation CCA Common Country Assessment CCTV Central Chinese Television CNY Chinese Yuan (December 2001: 1USD = 8.26 Chinese Yuan) DALY Disability Adjusted Life Year GONGO Government-organised NGO GIPA Greater Involvement of People Infected with or Affected by HIV/AIDS HIV Human Immunodeficiency Virus IEC Information Education Communication IDU Injecting Drug User KAP Knowledge Attitude Practice MOH Ministry of Health MSF Médecins Sans Frontières NGO Non-governmental Organisation PAF Programme Acceleration Funds PLWHA People Living with HIV/AIDS RTI Reproductive Tract Infections SFPC The State Family Planning Commission STD Sexually Transmitted Diseases STI Sexually Transmitted Infections TB Tuberculosis UNAIDS Joint United Nations Programme on HIV/AIDS UNDAF United Nations Development Assistance Framework UNDCP United Nations Drug Control Programme UNDP United Nations Development Programme UNFPA United Nations Population Fund UNGASS United Nations General Assembly Special Session on HIV/AIDS UNICEF United Nations Children’s Fund USD United States Dollar UNTG United Nations Theme Group -
Demetre C Daskalakis MD
Demetre C Daskalakis MD MPH New York City Department of Health and Mental Hygiene 42-09 28th Street, Long Island City, NY 11101 Cell: 347-989-5513 Office: 347-396-7728 [email protected] EDUCATION Degree Programs: 2012 Harvard School of Public Health Boston, MA Masters of Public Health 1999 NYU School of Medicine New York, NY Medical Doctor 1995 Columbia University New York, NY Bachelor of Arts Post-Graduate Medical Training: 1999-2002 Harvard- Beth Israel Deaconess Boston, MA Residency (Medicine) 2002-2003 Harvard- Beth Israel Deaconess Boston, MA Chief Residency 2003-2005 Harvard-Partners Healthcare Boston, MA Fellowship (Infectious Dis) PROFESSIONAL EXPERIENCE 2017-Current New York City Department of Health and Mental Hygiene Deputy Commissioner- Division of Disease Control Oversee all infectious disease related public health programming at the NYC Department of Health, including: . Bureau of HIV . Bureau of Sexually Transmitted Infections . Bureau of Tuberculosis . Bureau of Communicable Diseases (Including Viral Hepatitis) . Public Health Laboratory . Bureau of Immunization . Bureau of Administration Over 1000 employees, 13 direct service clinical sites Oversee budget of nearly $300,000,000 Notable experience: o Coordinated response to local Legionella Clusters including coordination of epidemiology, environmental health, and lab responses including clusters related to cooling towers in Lenox Hill, Flushing, and Upper Washington Heights o Re-established funding for Tuberculosis Clinics and Field Services after drastic -
Are We Standing in Our Own Way on the Path to a Cure for HIV/AIDS
PROFILE Are we standing in our own way on the path to a cure for HIV/AIDS lthough there are many reasons to celebrate the life-extending benefits from antiretroviral Atherapeutics (ART) for HIV/AIDS and the ability to chronically manage patients’ disease for decades, the majority of people around the world living with the virus do not have access to ART and those that do, have over decades developed life-threatening side effects. Our inability to identify a cure to HIV lies not only in the as-of- yet failure of the medical research community to identify and develop appropriate means of ridding the body of the virus but also government and industrial policies that promote public opinion exclusively focused on chronic management scenarios instead of broadly exploring innovation for cure. “An inconvenient truth” (Davis Guggenheim) mates of the magnitude of the global forced government policy for early epidemic. As the majority of Ameri - and expanded access to experimental There are approximately 37 million cans are not rountinely tested for HIV, drugs, the medical community and people living with HIV and 39 million the virus can go years without being society are struggling with the fact have died of AIDS-related diseases diagnosed in an HIV positive person. that we are barely managing the HIV since the start of the epidemic in 1981. With these statistics it is no wonder epidemic and AIDS crisis. For years we As of March 2015, only 15 million that every day an estimated 5,600 have been locked into thinking of people have access to treatments for people globally become newly infected solutions in terms of a chronic disease HIV. -
Annual Report 2018-2019
ANNUAL REPORT 2018-2019 1 2 CONTENTS A Letter from Our Executive Director 4 A Letter from the Chair of the Board 5 Our Namesakes 6 Celebrating Our History: 50 Years of LGBTQ Health 8 Timeline 12 Reflections on our History 14-17 Our Patients 18 A Year in Photos 22 Our Staff 24 Callen-Lorde Brooklyn 26 Board of Directors 28 Senior Leadership 29 Howard J. Brown Society 30 Our Supporters 32 ABOUT US Callen-Lorde is the global leader in LGBTQ healthcare. Since the days of Stonewall, we have been transforming lives in LGBTQ communities through excellent comprehensive care, provided free of judgment and regardless of ability to pay. In addition, we are continuously pioneering research, advocacy and education to drive positive change around the world, because we believe healthcare is a human right. 3 A LETTER FROM OUR EXECUTIVE DIRECTOR Dear Friends, Supporters, and Community Members, Fifty years ago, Sylvia Rivera and Marsha P. Johnson were among the first brick throwers in the Stonewall Rebellions, igniting the fire that began – slowly – to change LGBTQ lives. That same year, the beginnings of Callen- Lorde started when two physicians opened the St. Mark’s Health Clinic to provide free healthcare services to the ‘hippies, freaks, and queers’ in the East Village. Today, that little clinic is Callen-Lorde Community Health Center - a network of health centers soon to be in three boroughs of New York City and improving LGBTQ health worldwide. What has not changed in 50 years is our commitment to serving people regardless of ability to pay, our passion for health equity and justice for our diverse LGBTQ communities and people living with HIV, and our belief that access to healthcare is a human right and not a privilege. -
HIV Genotyping and Phenotyping AHS – M2093
Corporate Medical Policy HIV Genotyping and Phenotyping AHS – M2093 File Name: HIV_genotyping_and_phenotyping Origination: 1/2019 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Description Human immunodeficiency virus (HIV) is an RNA retrovirus that infects human immune cells (specifically CD4 cells) causing progressive deterioration of the immune system ultimately leading to acquired immune deficiency syndrome (AIDS) characterized by susceptibility to opportunistic infections and HIV-related cancers (CDC, 2014). Related Policies Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection Scientific Background Human immunodeficiency virus (HIV) targets the immune system, eventually hindering the body’s ability to fight infections and diseases. If not treated, an HIV infection may lead to acquired immunodeficiency syndrome (AIDS) which is a condition caused by the virus. There are two main types of HIV: HIV-1 and HIV-2; both are genetically different. HIV-1 is more common and widespread than HIV-2. HIV replicates rapidly; a replication cycle rate of approximately one to two days ensures that after a single year, the virus in an infected individual may be 200 to 300 generations removed from the initial infection-causing virus (Coffin & Swanstrom, 2013). This leads to great genetic diversity of each HIV infection in a single individual. As an RNA retrovirus, HIV requires the use of a reverse transcriptase for replication purposes. A reverse transcriptase is an enzyme which generates complimentary DNA from an RNA template. This enzyme is error-prone with the overall single-step point mutation rate reaching ∼3.4 × 10−5 mutations per base per replication cycle (Mansky & Temin, 1995), leading to approximately one genome in three containing a mutation after each round of replication (some of which confer drug resistance). -
ACT up by Geoffrey W
ACT UP by Geoffrey W. Bateman Encyclopedia Copyright © 2015, glbtq, Inc. Entry Copyright © 2004, glbtq, inc. Reprinted from http://www.glbtq.com On March 24, 1987, the AIDS Coalition To Unleash Power, or ACT UP, staged its first action in New York City on Wall Street, protesting the Food and Drug Administration and the drug company Burroughs Wellcome. Converging on the site in the hundreds, protesters passed out flyers, disrupted traffic, and drew considerable media attention. One activist even built an effigy of the head of the FDA that he hung outside a church during the protest. Through this demonstration, ACT UP initiated its direct-action strategy in the fight against the AIDS epidemic. Using bold images and confrontational tactics, ACT UP worked to promote awareness of AIDS and challenge the complacency of politicians and government officials who had yet to respond adequately to the crisis. As its statement of purpose reads, "ACT UP is a diverse, non-partisan group united in anger and committed to direct action to end the AIDS crisis. We protest and demonstrate; we meet with government and public health officials; we research and distribute the latest medical information; we are not silent." Targeting Wall Street allowed ACT UP to highlight one of the most pressing needs of those living with AIDS in the late 1980s--effective and affordable drug treatment. Because of FDA policies, Burroughs Wellcome was the only company that made and sold AZT. The high cost of the drug--anywhere from $10,000 to $13,000 a year for one patient--and the belief that it was the only treatment option available prompted New York City activists to target this monopoly.